A judge has suggested that a class action against the New South Wales government over a mandate requiring healthcare workers to be vaccinated against COVID-19 should be de-classed, saying it was a “straightforward point” because no financial relief was sought.
Israeli drug company Neurim Pharmaceuticals has won an eight month extension to apply for a grace period for its melatonin tablet patent to treat children with autism spectrum disorder after Australian company Generic Partners lost its “inherently implausible” opposition to the patent.
A former head of medical at Sanofi-Aventis has sued the Australian branch of the pharmaceutical giant, claiming he was unfairly dismissed in a “‘sham redundancy” and faced discrimination because of his age and disabilities.
Mylan’s Australia unit is appealing decisions by the tax office to refuse deductions on interest paid under loans taken out by the pharmaceutical giant to help fund the $1.2 billion acquisition of generic drug maker Alphapharm almost 15 years ago.
Bayer has lost its bid to redact the names and contact details of potential group members from discovered documents in a Slater & Gordon-led class action over the drug maker’s Essure contraceptive device.
The maker of the popular Invisalign dental aligners has sued competitor SmileDirectClub for allegedly misleading consumers about the cost and efficacy of its direct-to-consumer teeth alignment kits.
Swiss pharmaceutical company Biogen has won discovery of documents sent from Sandoz to the Therapeutic Goods Administration, as it weighs a third patent infringement lawsuit to protect its multiple sclerosis drug against generic reproductions.
IVF company Virtus Health has withdrawn its offer to acquire rival Adora Fertility from Healius, citing the competition regulator’s opposition to the takeover.
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.
Group members in a class action over Bayer’s Essure contraceptives had “a ticking time bomb” in their bodies after being implanted with the devices, and all were at risk of developing injuries, a court has heard.